The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C

F. Bellanti, G. Vendemiale, E. Altomare, G. Serviddio

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed.

Original languageEnglish
Article number849373
JournalClinical and Developmental Immunology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Interleukins
Hepatitis C
Interferons
Hepacivirus
Virus Diseases
Genes
Immunity
Therapeutics
Genome-Wide Association Study
Chronic Hepatitis C
Antiviral Agents
Single Nucleotide Polymorphism
Genotype
Infection

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. / Bellanti, F.; Vendemiale, G.; Altomare, E.; Serviddio, G.

In: Clinical and Developmental Immunology, Vol. 2012, 849373, 2012.

Research output: Contribution to journalArticle

@article{d2b9707e0cd84ae994aabd8dec8da779,
title = "The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C",
abstract = "Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed.",
author = "F. Bellanti and G. Vendemiale and E. Altomare and G. Serviddio",
year = "2012",
doi = "10.1155/2012/849373",
language = "English",
volume = "2012",
journal = "Clinical and Developmental Immunology",
issn = "1740-2522",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C

AU - Bellanti, F.

AU - Vendemiale, G.

AU - Altomare, E.

AU - Serviddio, G.

PY - 2012

Y1 - 2012

N2 - Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed.

AB - Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed.

UR - http://www.scopus.com/inward/record.url?scp=84866178019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866178019&partnerID=8YFLogxK

U2 - 10.1155/2012/849373

DO - 10.1155/2012/849373

M3 - Article

VL - 2012

JO - Clinical and Developmental Immunology

JF - Clinical and Developmental Immunology

SN - 1740-2522

M1 - 849373

ER -